Merck & Co Inc. Launches LIPFENDRA®: A Game-Changer in Cholesterol Management
1. FDA Approval of LIPFENDRA®
On July 16, 2026, Merck & Co Inc. (NYSE: MRK) announced a significant milestone in the pharmaceutical industry with the U.S. Food and Drug Administration (FDA) approval of LIPFENDRA® (enlicitide) tablets, a groundbreaking treatment for adults suffering from hypercholesterolemia. This marks the first and only once-daily oral proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor approved by the FDA, specifically designed to reduce low-density lipoprotein cholesterol (LDL-C), commonly referred to as "bad cholesterol."
Dr. Dean Y. Li, president of Merck Research Laboratories, expressed pride in this achievement, stating, “By harnessing the innovative science of PCSK9 inhibitors and novel macrocyclic peptide technology, LIPFENDRA was designed to significantly lower LDL-C in the form of a convenient once-daily pill.” He emphasized that this approval presents a vital new option for adults with elevated LDL-C levels, a major risk factor for cardiovascular diseases.
2. Clinical Trial Success
The FDA's approval of LIPFENDRA is anchored in the findings from two pivotal Phase 3 trials, part of the comprehensive CORALreef clinical program: CORALreef Lipids and CORALreef HeFH.
Results from CORALreef Lipids
In the CORALreef Lipids trial, which included 2,904 patients, LIPFENDRA demonstrated a remarkable 56% reduction in LDL-C at week 24 compared to placebo. When considering revised data handling rules that excluded biologically implausible baseline values, this reduction increased to 60%. Additionally, the treatment also yielded significant reductions in non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B (ApoB), which are also critical markers associated with atherosclerotic cardiovascular disease (ASCVD) risk.
Results from CORALreef HeFH
Similarly, in the CORALreef HeFH trial, which focused on patients with heterozygous familial hypercholesterolemia, LIPFENDRA achieved a 59% reduction in LDL-C at week 24. The results highlighted that LIPFENDRA effectively lowers other atherogenic lipoproteins, further accentuating its potential in managing cholesterol levels.
3. Safety Profile and Adverse Reactions
The safety profile of LIPFENDRA was consistent with placebo in the CORALreef Lipids trial, while the CORALreef HeFH trial noted a slightly higher incidence of diarrhea (7% vs. 2%) and dizziness (9% vs. 4%) among patients treated with LIPFENDRA compared to those receiving placebo. Notably, the study found similar rates of treatment discontinuation due to adverse reactions across both treatment groups.
4. Implications for Cardiovascular Health
Cardiovascular diseases remain the leading cause of death globally, primarily driven by high LDL-C levels. Dr. Ann Marie Navar, a lead author of the CORALreef Lipids study, emphasized the importance of LIPFENDRA's approval, stating, “In two Phase 3 trials, LIPFENDRA led to impressive reductions in LDL-C. Now, for the first time, patients have an oral PCSK9 inhibitor for LDL lowering.”
The ongoing clinical trials continue to explore LIPFENDRA's impact on cardiovascular morbidity and mortality, with the results yet to be determined.
5. The Path Forward
Katherine Wilemon, CEO of the Family Heart Foundation, welcomed the approval: “One of the greatest opportunities to help manage the risk of ASCVD lies in the timely identification and appropriate treatment of risk factors, such as LDL-C. We are encouraged by the approval of a new oral PCSK9 inhibitor option for adults who need additional LDL-C lowering.”
The CORALreef clinical trial program has involved over 19,000 participants and will continue to evaluate LIPFENDRA's efficacy and safety in various settings, including an ongoing cardiovascular outcomes trial, CORALreef Outcomes.
6. Conclusion
Merck's introduction of LIPFENDRA marks a transformative moment in cholesterol management, offering a novel therapeutic option for patients struggling with high LDL-C levels. As the pharmaceutical landscape evolves, LIPFENDRA stands as a testament to Merck's commitment to advancing cardiometabolic health solutions. The market response to this innovative treatment and ongoing research outcomes will be closely monitored as patients and healthcare providers alike look forward to improved cardiovascular health outcomes.
